Основная статистика
| CIK | 1173313 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ABVC BioPharma, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 15, 2025 |
ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276500 Registration No. 333-271416 Prospectus Supplement No. 4 Dated August 15, 2025 (To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock This Prospectus Supplement No. 4 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” |
|
| August 15, 2025 |
ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276500 Registration No. 333-271416 Prospectus Supplement No. 4 Dated August 15, 2025 (To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock This Prospectus Supplement No. 4 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” |
|
| August 15, 2025 |
ABVC BioPharma, Inc. 3,400,187 shares of Common Stock Underlying Common Stock Purchase Warrant Filed Pursuant to Rule 424(b)(4) Registration No. 333-250899 Prospectus Supplement No. 4 Dated August 15, 2025 (To Prospectus Dated August 7, 2024) ABVC BioPharma, Inc. 3,400,187 shares of Common Stock Underlying Common Stock Purchase Warrant This Prospectus Supplement No. 4 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Com |
|
| August 15, 2025 |
ABVC BioPharma, Inc. 225,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-255112 Prospectus Supplement No. 4 Dated August 15, 2025 (To Prospectus Dated May 22, 2024) ABVC BioPharma, Inc. 225,500 Shares of Common Stock This Prospectus Supplement No. 4 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated May 22, 20 |
|
| August 15, 2025 |
ABVC BioPharma, Inc. 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant Filed Pursuant to Rule 424(b)(4) Registration No. 333-280411 Prospectus Supplement No. 3 Dated August 15, 2025 (To Prospectus Dated July 12, 2024) ABVC BioPharma, Inc. 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Comp |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 ABVC BIOPHARMA, INC. |
|
| August 14, 2025 |
Exhibit 99.1 ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025 Silicon Valley, CA (August 14, 2025) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology/hematology, today announced |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. (Exa |
|
| July 18, 2025 |
Definitive Agreement between the Company and Shuling Jiang Exhibit 10.1 Definitive Agreement This Definitive Agreement (“Agreement”) is entered into as of July 15, 2025, by and between ABVC BioPharma, Inc. (“ABVC”), and Shuling Jiang (hereinafter referred to as “Shuling”). ABVC and Shuling are sometimes referred to herein individually as a “Party,” and collectively as the “Parties.” Due to strategically cooperate and construct an integrated platform for t |
|
| July 18, 2025 |
Exhibit 4.1 WARRANT AGREEMENT This WARRANT AGREEMENT (this “Agreement”) is entered into as of July 15, 2025 (the “Issue Date”), by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”), and Shuling Jiang (the “Holder”). This Agreement is issued pursuant to that certain Definitive Land Purchase Agreement between the Company and the Holder dated July 15, 2025 (the “Land Agreement”). |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 (February 8, 2024) ABVC BIOPHARMA, INC. |
|
| July 18, 2025 |
Exhibit 10.2 Consulting Agreement This Consulting Agreement (“Agreement”) is made and entered into as of July 15, 2025, by and between ABVC BioPharma, Inc., a Nevada corporation (“Company”), and Shuling Jiang (“Consultant”). WHEREAS, the Company desires to engage Consultant to provide certain land-related consulting services as described herein; WHEREAS, Consultant possesses the qualifications, kn |
|
| June 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ABVC BIOPHARMA, INC. |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025 As filed with the Securities and Exchange Commission on June 27, 2025 Registration No. |
|
| June 27, 2025 |
Second Amended and Restated 2016 Equity Incentive Plan Exhibit 10.3 SECOND AMENDED AND RESTATED ABVC BIOPHARMA, INC. 2016 EQUITY INCENTIVE PLAN SECTION 1. PURPOSE The purposes of this Second Amended and Restated 2016 Equity Incentive Plan (the "Plan") are to encourage selected employees, directors and consultants of ABVC BIOPHARMA, INC. (together with any successor thereto, the "Company") and its Affiliates (as defined below) to acquire a proprietary |
|
| June 4, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 ABVC BIOPHARMA, INC. |
|
| May 30, 2025 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 (April 30, 2025) ABVC BIOPHARMA, INC. |
|
| May 27, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025 As filed with the Securities and Exchange Commission on May 23, 2025 Registration No. |
|
| May 27, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025 As filed with the Securities and Exchange Commission on May 23, 2025 Registration No. |
|
| May 27, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025 As filed with the Securities and Exchange Commission on May 23, 2025 Registration No. |
|
| May 22, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 22, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 22, 2025 REGISTRATION NO. |
|
| May 22, 2025 |
Calculation of Filing Fee Table* Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ABVC BIOPHARMA, INC. |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 16, 2025 |
As filed with the Securities and Exchange Commission on May 16, 2025 As filed with the Securities and Exchange Commission on May 16, 2025 Registration No. |
|
| May 16, 2025 |
As filed with the Securities and Exchange Commission on May 16, 2025 As filed with the Securities and Exchange Commission on May 16, 2025 Registration No. |
|
| May 14, 2025 |
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance Exhibit 99.1 ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance Silicon Valley, CA – May 14, 2025 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that it has received official notice from the Nasdaq Listing Qualificatio |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 (April 30, 2025) ABVC BIOPHARMA, INC. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 (July 12, 2024 & January 13, 2025) ABVC BIOPHARMA, INC. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 (April 30, 2025) ABVC BIOPHARMA, INC. |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 (April 15, 2025) ABVC BIOPHARMA, INC. |
|
| May 1, 2025 |
Exhibit 99.1 ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan Silicon Valley, CA – May 01, 2025 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, oncology, and ophthalmology indications, today announced its financial resul |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 ABVC BIOPHARMA, INC. |
|
| April 30, 2025 |
Form of Purchase Agreement (58) Exhibit 10.1 ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd. Fremont, CA 94538 April [ ], 2025 Name: Address: RE: Securities Subscription Agreement Ladies and Gentlemen: ABVC BioPharma, Inc., a Nevada company (the “Company”), is pleased to accept the offer, an individual (the “Subscriber” or “you”), has made to subscribe for and purchase [ ] shares (the “Shares”), of the Company’s common stock, |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. (Ex |
|
| April 30, 2025 |
Form of Voting Rights Proxy Agreement (58) Exhibit 4.2 VOTING RIGHTS PROXY AGREEMENT This Voting Rights Proxy Agreement (this “Agreement”) is entered into as April [ ], 2024 (“Effective Date”), by and between (the “Shareholder”) and Eugene Jiang (“Jiang”). The Shareholder and Jiang are each referred to in this Agreement as a “Party” and collectively as the “Parties.” RECITALS A. The Shareholder is a member of ABVC BioPharma, Inc., a Nevada |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 ABVC BIOPHARMA, INC. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 16, 2025 |
Exhibit 99.1 ABVC BioPharma Announces 2024 Financial Results Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million1 Licensing Incomes Available Silicon Valley, CA (April 16, 2025) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leve |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 (April 15, 2025) ABVC BIOPHARMA, INC. |
|
| April 15, 2025 |
Yunzhiyi Land Holding Agreement dated October 28, 2024 (57) Exhibit 10.61 |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 ABVC BIOPHARMA, INC. |
|
| April 15, 2025 |
Nominee Holding Agreement dated April 1, 2024 (57) Exhibit 10.57 |
|
| April 15, 2025 |
Land Lease Agreement dated April 1, 2024 (57) Exhibit 10.58 |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40700 ABVC BioPharma, Inc. (Exact na |
|
| April 15, 2025 |
Addendum to Definitive Licensing Agreement between ABVC and AiBtl dated March 11, 2025 (57) Exhibit 10.59 Addendum to the Definitive Licensing Agreement This Addendum (“Addendum”) is entered into as of March 11, 2025, by and between: (1) ABVC BioPharma, Inc., a corporation organized under the laws of the State of Nevada (“ABVC”); and (2) AiBtl BioPharma Inc., a corporation organized under the laws of the State of Delaware (“AIBL”). This Addendum supplements the Definitive Licensing Agree |
|
| April 15, 2025 |
Exhibit 21.1 SUBSIDIARIES OF AND CONSOLIDATED ENTITIES OF ABVC BIOPHARMA, INC. As of December 31, 2024 Name of Subsidiary Jurisdiction of Incorporation Percentage of direct or indirect AiBtl BioPharma Inc. Delaware, United States 58.85 % American BriVision Corporation Delaware, United States 100 % BioKey, Inc. California, United States 100 % BioKey (Cayman), Inc. Cayman Islands 100 % BioLite Holdi |
|
| April 15, 2025 |
ABVC BioPharma Announces 2024 Financial Results Exhibit 99.1 ABVC BioPharma Announces 2024 Financial Results Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million1 Licensing Incomes Available Silicon Valley, CA (April 16, 2025) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leve |
|
| April 15, 2025 |
Addendum to Definitive Licensing Agreement between BioLite and AiBtl dated March 11, 2025 (57) Exhibit 10.60 Addendum to the Definitive Licensing Agreement This Addendum (“Addendum”) is entered into as of March 11, 2025, by and between: (1) BioLite Inc., a corporation organized under the laws of Taiwan(“BIOLITE”); and (2) AiBtl BioPharma Inc., a corporation organized under the laws of the State of Delaware (“AIBL”). This Addendum supplements the Definitive Licensing Agreement executed on No |
|
| April 15, 2025 |
Land Transfer Plan dated March 31, 2025 (57) Exhibit 10.56 AiBtl BioPharma Inc. Company Land Transfer Plan Background In response to Taiwan’s legal restrictions prohibiting foreign legal entities from directly registering farmland ownership, AiBtl BioPharma Inc. appointed three Taiwanese nationals — Ting, Huei-Hua, Fang, Ya-Rong, and Fang, Hsi-Chuan — to hold legal title to the land. The Company entered into a Nominee Holding Agreement and L |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40700 CUSIP Number: 0091F106 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11- |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 ABVC BIOPHARMA, INC. |
|
| February 14, 2025 |
EX-99.1 2 exhibit99-1.htm JOINT FILING APPLICATION BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING APPLICATION The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of ABVC BioPharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to suc |
|
| January 13, 2025 |
Exhibit 99.1 ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance with Nasdaq Bid Price Requirement Fremont, CA (January 13, 2025) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to announce that Nasdaq has granted the C |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 (July 12, 2024) ABVC BIOPHARMA, INC. |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 ABVC BIOPHARMA, INC. |
|
| January 6, 2025 |
Letter Agreement dated January 5, 2025 (56) Exhibit 10.1 January 5, 2025 Re: Inducement Offer to Exercise Existing Warrants to Purchase Common Stock Reference is made to that certain (i) Common Stock Purchase Warrant issued by ABVC Biopharma, Inc., a Nevada corporation (the “Company”) to Lind Global Fund II LP (the “Holder”), on February 23, 2023, to initially purchase 5,291,667 shares (529,167 shares after the after the July 2023 1-for-10 |
|
| November 15, 2024 |
ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276500 Registration No. 333-271416 Prospectus Supplement No. 3 Dated November 15, 2024 (To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we, |
|
| November 15, 2024 |
ABVC BioPharma, Inc. 3,400,187 shares of Common Stock Underlying Common Stock Purchase Warrant Filed Pursuant to Rule 424(b)(4) Registration No. 333-250899 Prospectus Supplement No. 3 Dated November 15, 2024 (To Prospectus Dated August 7, 2024) ABVC BioPharma, Inc. 3,400,187 shares of Common Stock Underlying Common Stock Purchase Warrant This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “C |
|
| November 15, 2024 |
ABVC BioPharma, Inc. 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant Filed Pursuant to Rule 424(b)(4) Registration No. 333-280411 Prospectus Supplement No. 2 Dated November 15, 2024 (To Prospectus Dated July 12, 2024) ABVC BioPharma, Inc. 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Co |
|
| November 15, 2024 |
ABVC BioPharma, Inc. 225,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-255112 Prospectus Supplement No. 3 Dated November 15, 2024 (To Prospectus Dated May 22, 2024) ABVC BioPharma, Inc. 225,500 Shares of Common Stock This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated May 22, |
|
| November 14, 2024 |
ABVC BioPharma Inc. Reports Q3 2024 Financial Results and Operational Milestones Exhibit 99.1 ABVC BioPharma Inc. Reports Q3 2024 Financial Results and Operational Milestones ● ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. ● Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in income ● Received Cash Milestone Incomes of $496,000 for the nine mont |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ABVC BIOPHARMA, INC. |
|
| November 14, 2024 |
ABVC / ABVC BioPharma, Inc. / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ABVC BioPharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00091F304 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of ABVC BioPharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Sc |
|
| November 4, 2024 |
Exhibit 10.1 November 1, 2024 Re: Inducement Offer to Exercise Outstanding Warrants to Purchase Common Stock Reference is made to that certain (i) Common Stock Purchase Warrant issued by ABVC Biopharma, Inc., a Nevada corporation (the “Company”) to Lind Global Fund II LP (the “Holder”), on February 23, 2023, to initially purchase 5,291,667 shares (529,167 shares after the after the July 2023 1-for |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 ABVC BIOPHARMA, INC. |
|
| October 25, 2024 |
ABVC BioPharma, Inc. 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant Filed Pursuant to Rule 424(b)(4) Registration No. 333-280411 Prospectus Supplement No. 1 Dated October 25, 2024 (To Prospectus Dated July 12, 2024) ABVC BioPharma, Inc. 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Com |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 ABVC BIOPHARMA, INC. |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 ABVC BIOPHARMA, INC. |
|
| August 20, 2024 |
Exhibit 99.1 Corporate Overview NASDAQ: ABVC 2024 2 Forward Looking Statements This presentation contains summary information about ABVC BioPharma, Inc . (“ABVC”) as of the date hereof . The information in this presentation is of general background and contains an overview and summary of certain data selected by the management of ABVC . It does not purport to be complete . This presentation is not |
|
| August 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 ABVC BIOPHARMA, INC. |
|
| August 16, 2024 |
ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276500 Registration No. 333-271416 Prospectus Supplement No. 2 Dated August 16, 2024 (To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” |
|
| August 16, 2024 |
ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276500 Registration No. 333-271416 Prospectus Supplement No. 2 Dated August 16, 2024 (To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” |
|
| August 16, 2024 |
ABVC BioPharma, Inc. 225,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-255112 Prospectus Supplement No. 2 Dated August 16, 2024 (To Prospectus Dated May 22, 2024) ABVC BioPharma, Inc. 225,500 Shares of Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated May 22, 20 |
|
| August 15, 2024 |
ABVC BioPharma Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements Exhibit 99.1 ABVC BioPharma Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements ● Executed Global Licensing Agreements that could provide up to $292 million in income ● Received Cash Milestone Incomes of $116,000 ● Achieved Significant Improvements in Earnings ● Obtained Multiple Patents and FDA Approvals Fremont, CA (August 15, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a c |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ABVC BIOPHARMA, INC. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. (Exa |
|
| August 7, 2024 |
ABVC BIOPHARMA, INC. 3,400,187 shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-250899 Prospectus Supplement No. 2 (To Prospectus dated July 26, 2024) ABVC BIOPHARMA, INC. 3,400,187 shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 3,400,187 shares of Common Stock of ABVC BioPharma, In |
|
| August 7, 2024 |
ABVC BIOPHARMA, INC. 3,400,187 shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-250899 Prospectus Supplement (To Prospectus dated July 26, 2024) ABVC BIOPHARMA, INC. 3,400,187 shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 3,400,187 shares of Common Stock of ABVC BioPharma, Inc., a |
|
| July 26, 2024 |
Letter in Lieu of Consent for Review Report (42) Exhibit 15.1 To the Board of Directors and Stockholders of ABVC BioPharma, Inc LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of ABVC BioPharma, Inc and its subsidiaries for the three-month periods ended March 31, 2024 a |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024 As filed with the Securities and Exchange Commission on July 26, 2024 Registration No. |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 ABVC BIOPHARMA, INC. |
|
| July 12, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 ABVC BIOPHARMA, INC. |
|
| July 12, 2024 |
1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-280411 PROSPECTUS 1,000,000 shares of Common Stock Underlying Common Stock Purchase Warrant This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 1,000,000 shares of Common Stock of ABVC BioPharma, Inc., a Nevada corporatio |
|
| June 27, 2024 |
ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd., Fremont, CA 94538 ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd., Fremont, CA 94538 VIA EDGAR June 27, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. Jason Drory Re: ABVC BioPharma, Inc. Registration Statement on Form S-1 File No. 333-280411 Filed on: June 21, 2024 Ladies and Gentlemen: Pursuant to Rule 461 under the |
|
| June 25, 2024 |
Amendment to the License Agreement between BioLite, Inc. and AiBtl BioPharma Inc. (55) Exhibit 10.2 Amendment Agreement This Amendment Agreement (the “Amendment”) is made and entered into as of June 23, 2024, by and between AiBtl BioPharma Inc., a Delaware State corporation, and BioLite, Inc., a Taiwan corporation. Recitals WHEREAS, the Company and the Counterparty entered into a definitive agreement dated November 12, 2023 (the “Definitive Agreement”); WHEREAS, the Definitive Agree |
|
| June 25, 2024 |
Amendment to the License Agreement between the Company and AiBtl BioPharma Inc. (55) Exhibit 10.1 Amendment Agreement This Amendment Agreement (the “Amendment”) is made and entered into as of June 23, 2024, by and between AiBtl BioPharma Inc., a Delaware State corporation, and ABVC BioPharma, Inc., a Nevada corporation. Recitals WHEREAS, the Company and the Counterparty entered into a definitive agreement dated November 12, 2023 (the “Definitive Agreement”); WHEREAS, the Definitiv |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 (November 16, 2023) ABVC BIOPHARMA, INC. |
|
| June 24, 2024 |
Exhibit 10.2 Amendment Agreement This Amendment Agreement (the “Amendment”) is made and entered into as of June 18, 2024, by and between ForSeeCon Eye Corporation, a British Virgin Islands corporation, and BioFirst Corporation, a Taiwan corporation. Recitals WHEREAS, the Company and the Counterparty entered into a definitive agreement dated March 25, 2024 (the “Definitive Agreement”); WHEREAS, the |
|
| June 24, 2024 |
Amendment to the Definitive License Agreement between the Company and ForSeeCon Eye Corporation (54) Exhibit 10.1 Amendment Agreement This Amendment Agreement (the “Amendment”) is made and entered into as of June 18, 2024, by and between ForSeeCon Eye Corporation, a British Virgin Islands corporation, and ABVC BioPharma, Inc., a Nevada corporation. Recitals WHEREAS, the Company and the Counterparty entered into a definitive agreement dated March 25, 2024 (the “Definitive Agreement”); WHEREAS, the |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 (March 26, 2024) ABVC BIOPHARMA, INC. |
|
| June 21, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 ABVC BioPharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule (1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (3) Equity Common Stock, $0.001 par value, issuable upon exercise of the Lind Warra |
|
| June 21, 2024 |
As filed with the Securities and Exchange Commission on June 21, 2024 As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| May 24, 2024 |
Definitive License Agreement between Biolite, Inc. and OncoX BioPharma, Inc. dated May 23, 2024 (53) Exhibit 10.2 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this May 23, 2024 (the “Effective Date”) by and between: (1) BIOLITE, INC., a company registered in Taiwan. (“BIOLITE”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and BIOLITE and ONCOX shall be referred to individually as a “Party” and co |
|
| May 24, 2024 |
Exhibit 99.1 Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (May 24, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS |
|
| May 24, 2024 |
Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 23, 2024 (53) Exhibit 10.1 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this May 23, 2024 (the “Effective Date”) by and between: (1) ABVC BioPharma, Inc., a company registered in Nevada. (“ABVC”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and ABVC and ONCOX shall be referred to individually as a “Party” and c |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 ABVC BIOPHARMA, INC. |
|
| May 23, 2024 |
ABVC BioPharma, Inc. 225,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-255112 Prospectus Supplement No. 1 Dated May 23, 2024 (To Prospectus Dated May 22, 2024) ABVC BioPharma, Inc. 225,500 Shares of Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated May 22, 2024, |
|
| May 23, 2024 |
Lind Letter Agreement dated May 22, 2024 (52) Exhibit 10.1 May 22, 2024 Re: Inducement Offer to Exercise Existing Warrants to Purchase Common Stock Reference is made to that certain (i) Common Stock Purchase Warrant issued by ABVC Biopharma, Inc., a Nevada corporation (the “Company”) to Lind Global Fund II LP (the “Holder”), on February 23, 2023, to initially purchase 5,291,667 shares (529,167 shares after the after the July 2023 1-for-10 rev |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 ABVC BIOPHARMA, INC. |
|
| May 23, 2024 |
Lind Form of Warrant dated May 22, 2024 (52) Exhibit 10.2 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI |
|
| May 22, 2024 |
ABVC BIOPHARMA, INC. 225,500 Shares of Common Stock Underlying Previously Issued Warrants Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-255112 PROSPECTUS ABVC BIOPHARMA, INC. 225,500 Shares of Common Stock Underlying Previously Issued Warrants This prospectus relates to the offer and sale by ABVC Biopharma, Inc., a Nevada corporation of up to 225,500 shares of common stock underlying warrants previously issued by us that are issuable at a price of $62.5 per share from |
|
| May 22, 2024 |
ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-276500 Registration No. 333-271416 Prospectus Supplement No. 1 Dated May 22, 2024 (To Prospectus Dated April 5, 2024) ABVC BioPharma, Inc. 11,714,683 Shares of Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 (February 8, 2024) ABVC BIOPHARMA, INC. |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. (Ex |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (CHECK ONE): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transac |
|
| May 15, 2024 |
Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 14, 2024 Exhibit 10.1 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this May 14, 2024 (the “Effective Date”) by and between: (1) ABVC BioPharma, Inc., a company registered in Nevada. (“ABVC”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and ABVC and ONCOX shall be referred to individually as a “Party” and c |
|
| May 15, 2024 |
Exhibit 99.1 Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M Fremont, CA (May 16, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), |
|
| May 15, 2024 |
Definitive License Agreement between Biolite, Inc. and OncoX BioPharma, Inc. dated May 14, 2024 Exhibit 10.2 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this May 14, 2024 (the “Effective Date”) by and between: (1) BIOLITE, INC., a company registered in Taiwan. (“BIOLITE”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and BIOLITE and ONCOX shall be referred to individually as a “Party” and co |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 ABVC BIOPHARMA, INC. |
|
| May 9, 2024 |
Exhibit 99.1 Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (May 09, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous sys |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ABVC BIOPHARMA, INC. |
|
| May 9, 2024 |
Definitive License Agreement between Rgene and OncoX BioPharma, Inc. dated May 8, 2024 (51) Exhibit 10.2 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this May 08, 2024 (the “Effective Date”) by and between: (1) RGENE Corporation, a company registered in Taiwan. ("RGENE"); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and RGENE and ONCOX shall be referred to individually as a “Party” and co |
|
| May 9, 2024 |
Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 8, 2024 (51) Exhibit 10.1 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this May 08, 2024 (the “Effective Date”) by and between: (1) ABVC BioPharma, Inc., a company registered in Nevada. (“ABVC”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and ABVC and ONCOX shall be referred to individually as a “Party” and c |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2024 |
As filed with the Securities and Exchange Commission on April 25, 2024 As filed with the Securities and Exchange Commission on April 25, 2024 Registration No. |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 ABVC BIOPHARMA, INC. |
|
| April 17, 2024 |
Definitive License Agreement between Rgene and OncoX BioPharma, Inc. (48) Exhibit 10.2 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this April 16, 2024 (the “Effective Date”) by and between: (1) Rgene Corporation., a company registered in Nevada. (“RGENE”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and RGENE and ONCOX shall be referred to individually as a “Party” and |
|
| April 17, 2024 |
Exhibit 99.1 ABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (April 16, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematolo |
|
| April 17, 2024 |
Definitive License Agreement between the Company and OncoX BioPharma, Inc. (48) Exhibit 10.1 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this April 16, 2024 (the “Effective Date”) by and between: (1) ABVC BioPharma, Inc., a company registered in Nevada. (“ABVC”); and (2) OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and ABVC and ONCOX shall be referred to individually as a “Party” and |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 ABVC BIOPHARMA, INC. |
|
| April 5, 2024 |
ABVC BIOPHARMA, INC. 11,714,683 shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-276500 Registration Statement No. 333-271416 ABVC BIOPHARMA, INC. 11,714,683 shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 11,714,683 shares of Common Stock of ABVC BioPharma, Inc., |
|
| March 29, 2024 |
ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd., Fremont, CA 94538 ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd., Fremont, CA 94538 VIA EDGAR March 29, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Ms. Jessica Dickerson Re: ABVC BioPharma, Inc. Amendment to Registration Statement on Form S-1, as amended File No. 333-276500 File No. 333-271416 Ladies and Gentlemen: Pu |
|
| March 26, 2024 |
ABVC Biopharma Entered into a Global Licensing Deal of Vitargus Exhibit 99.1 ABVC Biopharma Entered into a Global Licensing Deal of Vitargus® with Licensing Income of $33.5M and Royalties up to $60M Fremont, CA (March 26, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Co |
|
| March 26, 2024 |
Definitive License Agreement between BioFirst Corporationand ForSeeCon Eye Corporation (49) Exhibit 10.2 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this 25 March, 2024 (the “Effective Date”) by and between: (1) BIOFIRST CORPORATION, (“BIOFIRST”) a company registered in Taiwan, (2) ForSeeCon Eye Corporation(“FEYE”), a company registered in the British Virgin Islands. BIOFIRST and FEYE shall be referred to individually as a “Party” and |
|
| March 26, 2024 |
Definitive License Agreement between the Company and ForSeeCon Eye Corporation (49) Exhibit 10.1 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this 25 March, 2024 (the “Effective Date”) by and between: (1) ABVC BioPharma, Inc., (“ABVC”) a company registered in the United States of America, (2) ForSeeCon Eye Corporation (“FEYE”), a company registered in the British Virgin Islands. ABVC and FEYE shall be referred to individually as |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 ABVC BIOPHARMA, INC. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 22, 2024 |
Bylaws of the Company, as amended (48) Exhibit 3.2 BYLAWS OF ABVC BIOPHARMA, INC. A NEVADA CORPORATION TABLE OF CONTENTS ARTICLE PAGE ARTICLE I OFFICES 1 Section 1.1 Business Office 1 Section 1.2 Registered Office 1 Section 1.3 Principal Office 1 ARTICLE II SHAREHOLDERS 1 Section 2.1 Annual Shareholder Meeting 1 Section 2.2 Special Shareholder Meetings 1 Section 2.3 Place of Shareholder Meetings 1 Section 2.4 Notice of Shareholder Meet |
|
| March 22, 2024 |
As filed with the Securities and Exchange Commission on March 22, 2024 As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| March 15, 2024 |
Policy For Recovery of Erroneously Awarded Incentive Compensation (45) Exhibit 97 ABVC BioPharma, Inc. Policy for RECOVERY OF ERRONEOUSLY AWARDED Incentive Compensation Effective December 1, 2023 1. INTRODUCTION ABVC BioPharma, Inc. (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circumstances. Th |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40700 ABVC BioPharm |
|
| March 15, 2024 |
Exhibit 19.1 ABVC BIOPHARMA, INC. INSIDER TRADING POLICY Effective December 1, 2023 A. INTRODUCTION ABVC BIOPHARMA, INC., a Nevada corporation (the “Company”), recognizes that its directors, officers, and other employees may invest from time to time in the common stock of the Company. However, all of the Company’s employees must exercise caution to conduct these transactions in compliance with app |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 ABVC BIOPHARMA, INC. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 ABVC BIOPHARMA, INC. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A ––––––––––––––––––––––––––––––– Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| March 14, 2024 |
Exhibit 3.1 Amendment to Bylaws Section 2.8: Shareholder Quorum and Voting Requirements. If the articles of incorporation or the Act provides for voting by a single voting group on a matter, action on that matter is taken when voted upon by that voting group. Shares entitled to vote as a separate voting group may take action on a matter at a meeting only if a quorum of those shares exists with res |
|
| March 14, 2024 |
Exhibit 99.1 ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update Fremont, CA (March 14, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. Th |
|
| March 13, 2024 |
Exhibit 21.1 SUBSIDIARIES OF AND CONSOLIDATED ENTITIES OF ABVC BIOPHARMA, INC. As of December 31, 2023 Name of Subsidiary Jurisdiction of Incorporation Percentage of direct or indirect AiBtl BioPharma Inc. Delaware, United States 60.55 % American BriVision Corporation Delaware, United States 100 % BioKey, Inc. California, United States 100 % BioLite Holding, Inc. Nevada, United States 100 % BioLit |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40700 ABVC BioPharma, Inc. (Exact na |
|
| February 29, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 (January 16, 2024) ABVC BIOPHARMA, INC. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 (November 20, 2023) ABVC BIOPHARMA, INC. |
|
| February 29, 2024 |
Amendment No. 1 to 3rd Lind Note (43) Exhibit 10.2 AMENDMENT NO. 1 TO SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 to Senior Convertible Promissory Note (this “Amendment”) is entered into as of February [ ], 2024 (the “Amendment Date”), by and between Lind Global fund II LP, a Delaware limited partnership (“Holder”), and ABVC BioPharma, Inc., a Nevada corporation (“Maker”). Capitalized terms used in this Amendment without |
|
| February 29, 2024 |
Amendment No. 2 to 2nd Lind Note (42) Exhibit 10.2 AMENDMENT NO. 2 TO SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 to Senior Convertible Promissory Note (this “Amendment”) is entered into as of February [ ], 2024 (the “Amendment Date”), by and between Lind Global fund II LP, a Delaware limited partnership (“Holder”), and ABVC BioPharma, Inc., a Nevada corporation (“Maker”). Capitalized terms used in this Amendment without |
|
| February 16, 2024 |
February 16, 2024 Via Edgar Alan Campbell Division of Corporation Finance Office of Life Sciences U. |
|
| February 16, 2024 |
As filed with the Securities and Exchange Commission on February 16, 2024 As filed with the Securities and Exchange Commission on February 16, 2024 Registration No. |
|
| February 13, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of ABVC BioPharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Sc |
|
| February 13, 2024 |
US00091F3047 / ABVC BIOPHARMA INC / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ABVC BioPharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00091F304 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 9, 2024 |
Form of 3rd Placement Agent Warrant (40) Exhibit 10.41 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVA |
|
| February 9, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1/A ABVC BioPharma, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (5) Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| February 9, 2024 |
Letter in Lieu of Consent for Review Report (45) Exhibit 15.1 To the Board of Directors and Stockholders of ABVC BioPharma, Inc LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of ABVC BioPharma, Inc and its subsidiaries for the nine-month periods ended September 30, 202 |
|
| February 9, 2024 |
February 9, 2024 Via Edgar Alan Campbell Division of Corporation Finance Office of Life Sciences U. |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 8, 2024 |
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Exhibit 99.1 ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Fremont, CA, February 08, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan |
|
| February 8, 2024 |
Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAIL |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 ABVC BIOPHARMA, INC. |
|
| February 8, 2024 |
Exhibit 10.1 Definitive Agreement This Definitive Agreement (“Agreement”) is entered into as of February 06, 2024, by and between ABVC BioPharma, Inc. (“ABVC”), and Shuling Jiang (hereinafter referred to as “Shuling”). ABVC and Shuling are sometimes referred to herein individually as a “Party,” and collectively as the “Parties.” Due to strategically cooperate and construct an integrated platform f |
|
| January 26, 2024 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To: The Board of Directors and Stockholders of AiBtl BioPharma Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of AiBtl BioPharma Inc. (the “Company”) as of September 30, 2023, and the related statements of operations and comprehensive loss, cash flows and stockholders’ deficit for the per |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 (November 16, 2023) ABVC BIOPHARMA, INC. |
|
| January 26, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”, or the acquired company) for the Company and BioLite’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention De |
|
| January 17, 2024 |
Second Amendment To Security Agreement (39) Exhibit 10.4 SECOND AMENDMENT TO SECURITY AGREEMENT This SECOND AMENDMENT TO SECURITY AGREEMENT (the “Amendment”) is dated effective as of January , 2024 (the “Amendment Effective Date”), by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”) and Lind Global Fund II LP (“Lind” and together with the Company, the “Parties”). RECITALS WHEREAS, the Company and Lind entered into and |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 ABVC BIOPHARMA, INC. |
|
| January 17, 2024 |
Securities Purchase Agreement dated January 17, 2024 (39) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of January , 2024, by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”), and Lind Global Fund II LP, a Delaware limited partnership (the “Investor”). BACKGROUND A. The board of directors (the “ |
|
| January 17, 2024 |
Amendment No. 1 to 2nd Lind Note (41) Exhibit 10.2 AMENDMENT NO. 1 TO SECURED CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 to Senior Convertible Promissory Note (this “Amendment”) is entered into as of January 12, 2024, by and between Lind Global fund II LP, a Delaware limited partnership (“Lender”), and ABVC BioPharma, Inc., a Nevada corporation (“Borrower”). Capitalized terms used in this Amendment without definition shall have |
|
| January 17, 2024 |
Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILAB |
|
| January 17, 2024 |
Exhibit 10.3 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI |
|
| January 17, 2024 |
Second Amendment to Guaranty (39) Exhibit 10.6 SECOND AMENDMENT TO GUARANTY This SECOND AMENDMENT TO GUARANTY AGREEMENT (the “Amendment”) is dated effective as of January , 2024 (the “Amendment Effective Date”), by and among American BriVision Corporation, a Delaware corporation (“American BriVision”), BioKey, Inc., a California corporation (“BioKey”), BioLite Holding, Inc., a Nevada corporation (“BioLite”), BioLite BVI, Inc., a B |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 (November 20, 2023) ABVC BIOPHARMA, INC. |
|
| January 17, 2024 |
Second Amendment To Guarantor Security Agreement (39) Exhibit 10.5 SECOND AMENDMENT TO GUARANTOR SECURITY AGREEMENT This SECOND AMENDMENT TO GUARANTOR SECURITY AGREEMENT (the “Amendment”) is dated effective as of January , 2024 (the “Amendment Effective Date”), by and among American BriVision Corporation, a Delaware corporation (“American BriVision”), BioKey, Inc., a California corporation (“BioKey”), BioLite Holding, Inc., a Nevada corporation (“Bio |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 ABVC BIOPHARMA, INC. |
|
| January 12, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 ABVC BioPharma, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (4) Carry Forward Form Type Carry Forward File Number Carry Forwar |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. |
|
| January 12, 2024 |
Letter in Lieu of Consent for Review Report Exhibit 15.1 To the Board of Directors and Stockholders of ABVC BioPharma, Inc LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of ABVC BioPharma, Inc and its subsidiaries for the nine-month periods ended September 30, 202 |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 20, 2023 |
First Amendment to Guaranty (38) Exhibit 10.6 EXECUTION VERSION FIRST AMENDMENT TO GUARANTY This FIRST AMENDMENT TO GUARANTY AGREEMENT (the “Amendment”) is dated effective as of November 17, 2023 (the “Amendment Effective Date”), by and among American BriVision Corporation, a Delaware corporation (“American BriVision”), BioKey, Inc., a California corporation (“BioKey”), BioLite Holding, Inc., a Nevada corporation (“BioLite”), Bio |
|
| November 20, 2023 |
Exhibit 10.3 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI |
|
| November 20, 2023 |
First Amendment To Guarantor Security Agreement (38) Exhibit 10.5 EXECUTION VERSION FIRST AMENDMENT TO GUARANTOR SECURITY AGREEMENT This FIRST AMENDMENT TO GUARANTOR SECURITY AGREEMENT (the “Amendment”) is dated effective as of November 17, 2023 (the “Amendment Effective Date”), by and among American BriVision Corporation, a Delaware corporation (“American BriVision”), BioKey, Inc., a California corporation (“BioKey”), BioLite Holding, Inc., a Nevad |
|
| November 20, 2023 |
Securities Purchase Agreement dated November 17, 2023 (38) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of November 17, 2023, by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”), and Lind Global Fund II LP, a Delaware limited partnership (the “Investor”). BACKGROUND A. The board of directors (th |
|
| November 20, 2023 |
Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILAB |
|
| November 20, 2023 |
First Amendment To Security Agreement (38) Exhibit 10.4 EXECUTION VERSION FIRST AMENDMENT TO SECURITY AGREEMENT This FIRST AMENDMENT TO SECURITY AGREEMENT (the “Amendment”) is dated effective as of November 17, 2023 (the “Amendment Effective Date”), by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”) and Lind Global Fund II LP (“Lind” and together with the Company, the “Parties”). RECITALS WHEREAS, the Company and Lin |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 ABVC BIOPHARMA, INC. |
|
| November 17, 2023 |
ABVC BioPharma, Inc. 4,575,923 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-250899 Prospectus Supplement No. 3 Dated November 17, 2023 (To Prospectus Dated April 26, 2023) ABVC BioPharma, Inc. 4,575,923 Shares of Common Stock This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated Apri |
|
| November 17, 2023 |
ABVC BioPharma, Inc. 9,031,112 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-271416 Prospectus Supplement No. 2 Dated November 17, 2023 (To Prospectus Dated June 12, 2023) ABVC BioPharma, Inc. 9,031,112 Shares of Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated June |
|
| November 17, 2023 |
ABVC BioPharma, Inc. 2,255,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-255112 Prospectus Supplement No. 3 Dated November 17, 2023 (To Prospectus Dated April 26, 2023) ABVC BioPharma, Inc. 2,255,000 Shares of Common Stock This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated Apri |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 ABVC BIOPHARMA, INC. |
|
| November 15, 2023 |
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results Exhibit 99.1 ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results FREMONT, CA, November 15, 2023 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the third quarter of 2023. These res |
|
| November 15, 2023 |
License Agreement between the BioLite and AiBtl BioPharma, Inc (47) Exhibit 10.41 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this 12 November, 2023 (the “Effective Date”) by and between: (1) BioLite, Inc., a corporation organized and existing and under the laws of Republic of China (“BioLite”); and (2) AiBtl BioPharma Inc., a corporation organized and existing and under the laws of the State of Delaware (“AIBL” |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. |
|
| November 15, 2023 |
License Agreement between the Company and AiBtl BioPharma, Inc (47) Exhibit 10.40 Definitive Licensing Agreement This Definitive Licensing Agreement (“Agreement”) is entered into this 12 November, 2023 (the “Effective Date”) by and between: (1) ABVC BioPharma, Inc., a corporation organized and existing and under the laws of the State of Nevada (“ABVC”); and (2) AiBtl BioPharma Inc., a corporation organized and existing and under the laws of the State of Delaware ( |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 ABVC BIOPHARMA, INC. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-40700 CUSIP NUMBER 00091F 304 (Check One): ¨ Form 10-K ☐ Form 20-F ¨ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K |
|
| September 13, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 ABVC BIOPHARMA, INC. |
|
| September 13, 2023 |
Exhibit 10.1 This waiver letter agreement (this “Waiver Letter”), to the senior convertible promissory note, dated as of February 23, 2023 (the “Note”), by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”) and Lind Global Fund II LP, a Delaware limited partnership (“Lind Global”), is made as of September 12, 2023. Unless otherwise indicated, capitalized terms shall have the me |
|
| September 6, 2023 |
Amendment to the Cooperation Agreement (36) Exhibit 10.1 AMENDMENT NO. 1 TO COOPERATION AGREEMENT This Amendment No. 1 (the “Amendment”) to cooperation agreement (the “Original Agreement”, the transaction contemplated herein the “Transaction”) is entered into as of August 28, 2023, by and between ABVC BioPharma, Inc. (“ABVC” or the “Company”), and 中汇聯和科技(成都)集團有限公司Zhonghui United Technology (Zhonghui) Group Co., Ltd. and its affiliated enter |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 (August 17, 2023) ABVC BIOPHARMA, INC. |
|
| August 31, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 ABVC BIOPHARMA, INC. |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ABVC BIOPHARMA, INC. |
|
| August 17, 2023 |
ABVC BioPharma, Inc. 2,255,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-255112 Prospectus Supplement No. 2 Dated August 16, 2023 (To Prospectus Dated April 26, 2023) ABVC BioPharma, Inc. 2,255,000 Shares of Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated April |
|
| August 17, 2023 |
Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (“Agreement”, the transaction contemplated herein the “Transaction”) is entered into as of August 14, 2023, by and between ABVC BioPharma, Inc. (“ABVC”), and Zhonghui United Technology (Chengdu) Group Co., Ltd. (“中汇联和科技(成都)集团有限公司”) and its affiliated enterprises (hereinafter referred to as “ZHONGHUI”). ABVC and ZHONGHUI are sometimes re |
|
| August 17, 2023 |
ABVC Executes Cooperation Agreement for Strategic Investments Exhibit 99.1 ABVC Executes Cooperation Agreement for Strategic Investments Fremont, CA, August 17, 2023 – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it had entered into a Cooperation Agreement to exchange a 20% ownership stake in real estate p |
|
| August 17, 2023 |
ABVC BioPharma, Inc. 4,575,923 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-250899 Prospectus Supplement No. 2 Dated August 16, 2023 (To Prospectus Dated April 26, 2023) ABVC BioPharma, Inc. 4,575,923 Shares of Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated April |
|
| August 17, 2023 |
ABVC BioPharma, Inc. 9,031,112 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333 - 271416 Prospectus Supplement No. 1 Dated August 16, 2023 (To Prospectus Dated June 12, 2023) ABVC BioPharma, Inc. 9,031,112 Shares of Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated June |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. (Exa |
|
| August 9, 2023 |
ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement Exhibit 99.1 ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement Fremont, CA (August 10, 2023) – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that on August 08, 2023, it received a letter from the Nasdaq Listing Qualificatio |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| August 7, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of ABVC BioPharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. August 7, 2023 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC it |
|
| August 7, 2023 |
ABVC Corporate Update and CEO’s Letter to Shareholders Exhibit 99.1 ABVC Corporate Update and CEO’s Letter to Shareholders Fremont, CA (August 07, 2023) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam |
|
| August 7, 2023 |
ABVC / ABVC BioPharma Inc / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ABVC BioPharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00091F106 (CUSIP Number) July 28, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 ABVC BIOPHARMA, INC. |
|
| August 2, 2023 |
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales Exhibit 99.1 ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales Fremont, CA (August 1, 2023) – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and ophthalmology, today announced the signing of a legally binding term sheet with a prominent Chinese pharmac |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 ABVC BIOPHARMA, INC. |
|
| August 2, 2023 |
Term Sheet dated July 31, 2023 Exhibit 10.1 Licensing Term Sheet This legal binding Term Sheet ( “Term Sheet”) shall take effect on the date of 31 July, 2023 (” Effective Date”). 本具有法律约束力的Term Sheet（“Term Sheet”）被视为于2023年7月 31 日（“生效日”）生效。 Between 缔约方: (1) ABVC BioPharma Inc., a company organized and existing under the Laws of United States of America, with its registered office at 44370 Old Warm Springs Boulevard, Fremont, Cali |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 ABVC BIOPHARMA, INC. |
|
| July 31, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-260588 Prospectus Supplement (To Prospectus dated November 16, 2021) ABVC BIOPHARMA, INC. 300,000 shares of Common Stock 200,000 Pre-Funded Warrants 200,000 shares of Common Stock underlying Pre-Funded Warrants Placement Agent Warrants to Purchase up to 30,000 shares of Common Stock (and the shares of Common Stock underlying such Placement Agen |
|
| July 31, 2023 |
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering Exhibit 99.1 ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering Fremont, CA (July 31, 2023) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has closed on a definitive securities purchase agreement with a single institution |
|
| July 27, 2023 |
Form of Securities Purchase Agreement, between the Company and the Purchasers Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 27, 2023, between ABVC BioPharma, Inc.., a company incorporated under the laws of Nevada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th |
|
| July 27, 2023 |
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering Exhibit 99.2 ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering Fremont, CA (July 27, 2023) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced it has entered into a definitive securities purchase agreement with a single institut |
|
| July 27, 2023 |
Exhibit 4.1 EXHIBIT A [FORM OF] PREFUNDED COMMON STOCK PURCHASE WARRANT ABVC BIOPHARMA, INC. Warrant Shares: [] Initial Exercise Date: THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [PURCHASER] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 ABVC BIOPHARMA, INC. |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 ABVC BIOPHARMA, INC. |
|
| July 24, 2023 |
Certificate of Amendment to Articles of Incorporation filed on July 24, 2023 (45) Exhibit 3.1 ARTICLES OF AMENDMENT ABVC BIOPHARMA, INC. 1. This Article of Amendment (the “Article of Amendment”) amends the provisions of the Corporation’s Articles of Incorporation filed with the Secretary of State in November 2001 (the “Certificate of Incorporation”). 2. That the Board of Directors of the Corporation duly adopted resolutions through a unanimous written consent setting forth the |
|
| July 24, 2023 |
ABVC BioPharma Announces Reverse Stock Split Exhibit 99.1 ABVC BioPharma Announces Reverse Stock Split Fremont, CA (July 24, 2023) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced a reverse stock split of its common stock (“Reverse Stock Split”) of one post-split share for every ten pre-split sha |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 ABVC BIOPHARMA, INC. |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 ABVC BIOPHARMA, INC. |
|
| June 23, 2023 |
Employment Agreement with Dr. Uttam Patil (42) Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is entered into by and between ABVC BioPharma, Inc., a Nevada company (“Employer”), and Uttam Yashwant Patil (“Employee”), to be effective on June 23, 2023 (the “Effective Date”). WHEREAS, Employer is desirous of employing Employee pursuant to the terms and conditions and for the consideration set forth in this Agreement, an |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 ABVC BIOPHARMA, INC. |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ABVC BIOPHARMA, INC. |
|
| June 12, 2023 |
ABVC BIOPHARMA, INC. 9,031,112 shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333 - 271416 ABVC BIOPHARMA, INC. 9,031,112 shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 3,527,778 shares of Common Stock of ABVC BioPharma, Inc., a Nevada corporation (the “Company”), |
|
| June 9, 2023 |
Exhibit 99.1 Cor p orate Overview N A SD A Q: ABVC 2023 This presentation contains summary information about ABVC BioPharma, Inc . (“ABVC”) as of the date hereof . The information in this presentation is of general background and contains an overview and summary of certain data selected by the management of ABVC . It does not purport to be complete . This presentation is not a prospectus, disclosu |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 ABVC BIOPHARMA, INC. |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 ABVC BIOPHARMA, INC. |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 7, 2023 |
ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd., Fremont, CA 94538 ABVC BioPharma, Inc. 44370 Old Warm Springs Blvd., Fremont, CA 94538 VIA EDGAR June 7, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. Tyler Howes Re: ABVC BioPharma, Inc. Amendment to Registration Statement on Form S-1, as amended (File No. 333-271416) Ladies and Gentlemen: Pursuant to Rule 461 under t |
|
| June 7, 2023 |
As filed with the Securities and Exchange Commission on June 7, 2023 As filed with the Securities and Exchange Commission on June 7, 2023 Registration No. |
|
| June 1, 2023 |
June 1, 2023 Via Edgar Tyler Howes Division of Corporation Finance Office of Life Sciences U. |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 As filed with the Securities and Exchange Commission on June 1, 2023 Registration No. |
|
| June 1, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 ABVC BioPharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule (1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (3) Equity Common Stock, $0.001par value, issuable upon conversion of the Note 457( |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 26, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 ABVC BIOPHARMA, INC. |
|
| May 22, 2023 |
ABVC BioPharma, Inc. 4,575,923 Shares of Common Stock 424B4 1 ea178843-424b4abvc.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(4) Registration No. 333 - 250899 Prospectus Supplement No. 1 Dated May 22, 2023 (To Prospectus Dated April 26, 2023) ABVC BioPharma, Inc. 4,575,923 Shares of Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporatio |
|
| May 22, 2023 |
ABVC BioPharma, Inc. 2,255,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333- 255112 Prospectus Supplement No. 1 Dated May 22, 2023 (To Prospectus Dated April 26, 2023) ABVC BioPharma, Inc. 2,255,000 Shares of Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of ABVC BioPharma, Inc., a Nevada corporation (the “Company,” “we,” “us,” or “our”) dated April 26 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40700 ABVC BioPharma, Inc. (Ex |
|
| May 10, 2023 |
As filed with the Securities and Exchange Commission on May 10, 2023 As filed with the Securities and Exchange Commission on May 10, 2023 Registration No. |
|
| May 10, 2023 |
May 10, 2023 Via Edgar Tyler Howes Division of Corporation Finance Office of Life Sciences U. |
|
| April 26, 2023 |
As filed with the Securities and Exchange Commission on April 26, 2023 As filed with the Securities and Exchange Commission on April 26, 2023 Registration No. |
|
| April 26, 2023 |
As filed with the Securities and Exchange Commission on April 26, 2023 As filed with the Securities and Exchange Commission on April 26, 2023 Registration No. |
|
| April 24, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 ABVC BIOPHARMA, INC. |
